Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM369
- Development stage
- Phase 1
- Lead developer
- Tiannuojiancheng Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CM369 is a potential first-in-class anti-C-C chemokine receptor type 8 (CCR8) monoclonal antibody developed for the treatment of various cancers. It is co-developed by InnoCare and Keymed through their joint venture Tiannuojiancheng Pharma. The drug targets CCR8 on regulatory T cells (Tregs) within the tumor microenvironment (TME), binding to CCR8 and depleting these immunosuppressive Tregs via antibody-dependent cellular cytotoxicity (ADCC). This selective depletion augments anti-tumor immunity while preserving peripheral immune homeostasis. As of early 2025, CM369 is in Phase I clinical trials for advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma[1][4][6][7].
02
Targets
CCR8CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on CM369.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM369.